A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
disclaimer for details.
ClinicalTrials.gov Identifier: NCT01560286
First Posted : March 22, 2012
Results First Posted : February 27, 2019
Last Update Posted : August 6, 2019
Information provided by (Responsible Party):
Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Biological: BMN 165 (rAvPAL-PEG)
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
Layout table for Results Point of Contact information
Sr. Medical Director, Clinical Science
BioMarin Pharmaceutical Inc
Layout table for additonal information
History of Changes
Other Study ID Numbers:
March 5, 2012
March 22, 2012
Results First Submitted:
June 22, 2018
Results First Posted:
February 27, 2019
Last Update Posted:
August 6, 2019